Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Salvarx Group

4 Jan 2019 17:30

RNS Number : 2703M
FTSE Russell
04 January 2019
 

 

 

 

 

Salvarx Group (UK): Constituent DeletionChanges in FTSE UK Index Series

04 January 2019

Subject to completion of the transaction with Portage Biotech (non-constituent) and the subsequent re-classification to AIM Rule 15 (cash shell) for Salvarx Group (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE AIM All-Share Index

09 January 2019

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSXZLFBKFFLBBX
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.